Thrombotic microangiopathy associated with proteasome inhibitors

Thrombotic microangiopathy associated with proteasome inhibitors

The ubiquitin proteasome pathway plays a key role in cell cycle, function and survival. Bortezomib (BTZ) and Carfilzomib (CFZ) are the first two inhibitors of the proteasome pathway, indicated in treatment of patients with multiple myeloma. In the past few years, there have been few case reports that have highlighted the association between proteasome inhibitors (BTZ and CFZ) with acute kidney ...

urinary tract infection associated with thrombotic microangiopathy

HIV associated thrombotic microangiopathy.

Thrombotic microangiopathy (TMA) is a known complication of HIV infection. Endothelial cell injury appears to be the primary event causing platelet activation and deposition in the microvasculature. Direct cytopathic roles of HIV as well as other factors such as malignancy, drugs, and infectious agents have been implicated in the pathogenesis of HIV-TMA. Although the the majority of patients pr...

Pregnancy Associated Thrombotic Microangiopathy

The thrombotic microangiopathies (TMA) are a group of common microvascular occlusive disorders characterized by thrombocytopenia, microangiopathic hemolysis and multiorgan dysfunction. The pathological features are vascular damage manifested by arteriolar and capillary thrombosis with characteristic abnormalities in the endothelium and vessel wall. Pregnancy associated TMA is a life threatening...

Cancer-associated thrombotic microangiopathy

Cancer-associated thrombotic microangiopathy refers to a group of disorders characterised by microvascular thrombosis, thrombocytopenia, and ischaemic end-organ damage. Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura are the two major subtypes. It can be a manifestation of the malignancy itself or a complication of its therapy. The addition of several new drugs to the therap...